Vita 34 AG (XTER:V3V) ROCE % : 0.62% (As of Sep. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Vita 34 AG ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vita 34 AG's annualized ROCE % for the quarter that ended in Sep. 2023 was 0.62%.

Vita 34 AG ROCE % Historical Data

The historical data trend for Vita 34 AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vita 34 AG ROCE % Chart

Vita 34 AG Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

3.80

4.90

4.05

-3.57

-26.57

Vita 34 AG Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
ROCE %	Get a 7-Day Free Trial															-1.16	-83.40	-8.27	-3.31	0.62

Vita 34 AG ROCE % Calculation

Vita 34 AG's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-26.245	/	( ( (177.946 - 63.375)	+	(151.508 - 68.527) )	/ 2 )
	=	-26.245	/	( (114.571	+	82.981)	/ 2 )
	=	-26.245	/	98.776
	=	-26.57 %

Vita 34 AG's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2023 )		(Q: Jun. 2023 )		(Q: Sep. 2023 )
	=	0.556	/	( ( (153.611 - 71.673)	+	(149.051 - 50.563) )	/ 2 )
	=	0.556	/	( ( 81.938	+	98.488 )	/ 2 )
	=	0.556	/	90.213
	=	0.62 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

Vita 34 AG (XTER:V3V) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Vita 34 AG ROCE % Related Terms

Thank you for viewing the detailed overview of Vita 34 AG's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Vita 34 AG (XTER:V3V) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Vita 34 AG (XTER:V3V) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

V3V:Germany V3V:Germany V3V:Germany

Address

Deutscher Platz 5a, Leipzig, DEU, D-04103

Website

https://www.vita34.de

Vita 34 AG is an umbilical cord blood bank. It supplies cryo-preservation and provides for the logistics to collect the blood, the preparation and the storage of stem cells from umbilical cord blood and tissue. The Group has two strategic areas that constitute the Group's reportable segments. Both segments are active in the field of stem cell banking, but differ in their organizational and operational structure with separate financial information. The products and services of the two segments correspond to the service portfolios of the two subgroups PBKM and Vita 34. It operates in Germany, Spain, and other international countries, of which maximum revenue is derived from the business operations in Germany.

Executives

Jakub Julian Baran	Member of the Management Board
Dr. Alexander Granderath	Supervisory Board

Vita 34 AG (XTER:V3V) Headlines

No Headlines